Boehringer Ingelheim obesity drug targets fat loss while preserving muscle in late-stage trial
Updated
Updated · The Wall Street Journal · Apr 28
Boehringer Ingelheim obesity drug targets fat loss while preserving muscle in late-stage trial
16 articles · Updated · The Wall Street Journal · Apr 28
Boehringer Ingelheim reports that Survodutide, its obesity drug, predominantly reduces visceral fat without significant muscle loss, according to CEO Shashank Deshpande.
Late-stage clinical data highlight Survodutide’s potential to improve the quality of weight loss by focusing on harmful fat stored around vital organs rather than overall body mass.
This approach could differentiate Survodutide in the rapidly growing weight-loss drug market, where many treatments also reduce muscle and lean tissue alongside fat.
Can a promising obesity drug succeed despite high patient dropout from side effects?
How does a new obesity drug melt hidden visceral fat while sparing muscle?
A new drug touts 'quality weight loss,' but can doctors accurately measure it?
Is 'quality of weight loss' a medical breakthrough or just clever marketing?
With Medicare expanding coverage, what is the true cost of next-gen obesity drugs?